Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Cynthia M, Hingtgen"'
Autor:
Staci Martin, Elizabeth K. Schorry, James H. Tonsgard, Heather L. Thompson, Pamela L. Wolters, Christopher J. Funes, Andrea Baldwin, Cynthia M. Hingtgen, Barbara Franklin, Stephanie Reeve, Taryn Allen, Taylor F. Smith, Kimberley S. Koetsier, Ana-Maria Vranceanu, Vanessa L. Merker, Carolina Barnett
Publikováno v:
Neurology
ObjectiveTo review and recommend patient-reported outcome (PRO) measures assessing multidimensional domains of quality of life (QoL) to use as clinical endpoints in medical and psychosocial trials for children and adults with neurofibromatosis (NF) t
Autor:
Pamela L, Wolters, Staci, Martin, Vanessa L, Merker, James H, Tonsgard, Sondra E, Solomon, Andrea, Baldwin, Amanda L, Bergner, Karin, Walsh, Heather L, Thompson, Kathy L, Gardner, Cynthia M, Hingtgen, Elizabeth, Schorry, William N, Dudley, Barbara, Franklin, Kaleb, Yohay
Publikováno v:
Neurology. 87:S4-S12
Objective: Tumors and other disease complications of neurofibromatosis (NF) can cause pain and negatively affect physical functioning. To document the clinical benefit of treatment in NF trials targeting these manifestations, patient-reported outcome
Autor:
Waylan K. Bessler, Brandon D. Downing, Kara N. Sarchet, Simon J. Conway, Lisa M. Kamendulis, Cynthia M. Hingtgen, Fang Li, D. Wade Clapp, Lucy C. Smiley, Daniel M. Hinds, Brian K. Stansfield, Jamie Case, David A. Ingram, Julie A. Mund, Matthew R. Distasi
Publikováno v:
Circulation. 129:1213-1224
Background— Neurofibromatosis type 1 (NF1) is a genetic disorder resulting from mutations in the NF1 tumor suppressor gene. Neurofibromin, the protein product of NF1 , functions as a negative regulator of Ras activity in circulating hematopoietic a
Publikováno v:
The Journal for Nurse Practitioners. 10:30-35
Von Recklinghausen or neurofibromatosis type 1 is an autosomal dominant condition that results in skin changes and noncancerous tumors along the nerves in the body. It is blind in regards to ethnicity, race, or sex. With a prevalence rate of 1 in 3,0
Autor:
James H. Tonsgard, Cynthia M. Hingtgen, Andrea Baldwin, Kathy Gardner, Elizabeth K. Schorry, Vanessa L. Merker, Pamela L. Wolters, Staci Martin
Publikováno v:
Neurology. 81:S6-S14
Objectives: Neurofibromatosis (NF) is a genetic disease with multiple clinical manifestations that can significantly impact quality of life (QOL). Clinical trials should include patient-reported outcomes (PROs) as endpoints to assess treatment effect
Publikováno v:
Neuroscience Letters. 496:70-74
Nerve growth factor (NGF) activates multiple downstream effectors, including Ras, phosphoinositide-3 kinase, and sphingomyelins. However, pathway mediating the NGF-induced augmentation of sensory neuronal excitability remains largely unknown. We prev
Autor:
Jill C. Fehrenbacher, Kellie A. Park, Cynthia M. Hingtgen, Djane B. Duarte, Eric L. Thompson, Michael R. Vasko
Publikováno v:
Neuroscience. 171:910-923
Nerve growth factor (NGF) can augment transmitter release in sensory neurons by acutely sensitizing sensory neurons and by increasing the expression of calcitonin gene-related peptide (CGRP) over time. The current study examined the intracellular sig
Publikováno v:
Neuroscience. 161:148-156
The glial cell line–derived neurotrophic factor (GDNF) family ligands (GFLs) are a group of peptides that have been implicated as important factors in inflammation, since they are released in increased amounts during inflammation and induce thermal
Autor:
Qiwei Zhang, Leslie A. Sitzman, Shanbao Cai, Cynthia M. Hingtgen, Mohammad Al-Hassani, Jeffrey B. Travers, Karen E. Pollok
Publikováno v:
Journal of Investigative Dermatology. 129(1):167-174
Ultraviolet B (UVB) radiation causes cutaneous inflammation. One important clinical consequence of UVB-induced inflammation is increased pain or hyperalgesia, which is likely mediated by enhanced sensitivity of cutaneous sensory neurons. Previous stu
Publikováno v:
The Laryngoscope. 117:917-922
Objective: Autologous muscle stem cell (myoblast) therapy may be an ideal treatment for vocal fold paralysis because of its technical ease (administered by injection), its potential to restore muscular defects and dynamic function, and its autologous